NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE American · Medical Instruments & Supplies · USD

Stereotaxis, Inc. (STXS) Stock Analysis

Stereotaxis, Inc. (STXS) is a Medical Instruments & Supplies stock listed on NYSE American and quoted in US Dollar.

STXS

$1.39

$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare STXS with… →

STXS Key Statistics

As of Sep 4, 2026
Trading
Open
$1.38
Previous Close
$1.39
Day's Range
1.38–1.41
52-Week Range
1.24–3.59
Volume
344.40K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.42
Valuation
Market Cap
$139.28M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.31
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.63
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.24
Financials (FY)
Revenue (FY)
$32.38M+20.28%
Net Income (FY)
−$21.64M
Profit marginThe share of revenue left as profit after all costs and taxes.
−74.24%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
100.20M
1-Year Return
−49.64%
Dividend and dates
Earnings Date
November 16, 2026
Avg Volume
829.48K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

STXS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−39.57%
2025+0.88%
2024+30.29%
2023−15.46%
2022−66.61%
2021+21.81%
2020−3.78%
2019+389.81%
2018+35.00%
2017+23.08%
2016 (partial year)−12.16%

As of September 4, 2026.

STXS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$32.38M−$21.64M−66.8%
2024$26.92M−$24.05M−89.3%
2023$26.77M−$20.71M−77.4%
2022$28.15M−$18.29M−65.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$32.38M$17.07M−$22.11M−$21.64M−66.8%
2024$26.92M$14.59M−$24.74M−$24.05M−89.3%
2023$26.77M$14.86M−$21.84M−$20.71M−77.4%
2022$28.15M$18.47M−$18.78M−$18.29M−65.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

STXS Valuation vs Medical Instruments & Supplies Median

Median of 55 stocks
MetricSTXSMedical Instruments & Supplies medianvs median
P/S ratio4.633.1746% above
Profit margin−74.24%0.85%75.1 pts below

Medians across 55 Medical Instruments & Supplies stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Stereotaxis, Inc. (STXS) is capitalised at $139.28M on the latest close. The company sits in the Healthcare sector, in the Medical Instruments & Supplies industry. The company reports 131 employees.

Over the past 52 weeks the price has ranged from $1.24 to $3.59. STXS last closed at $1.39 on September 4, 2026. The close was unchanged from the previous session. The latest close sits 12.1% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $32.38M. That is +20.28% against the prior fiscal year, when revenue was $26.92M. The same year closed with a net loss of $21.64M. Profit margin runs at −74.24%. That is 75.1 percentage points below the Medical Instruments & Supplies median of 0.85%. Earnings per share on a trailing basis come to −0.24.

Across the 4 fiscal years on file, revenue moves from $28.15M in 2022 to $32.38M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.31. The price-to-sales ratio is 4.63. On price-to-sales that is 46% above the Medical Instruments & Supplies median of 3.17. The medians here are taken across 55 Medical Instruments & Supplies companies that report the metric.

The trailing one-year price return is −49.64%. Measured over 10 years, that is +7.57% a year compounded. Beta against the wider market is reported at 1.42. Annualized volatility over the trailing 10 years is 72.81%.

Growth & Income

No dividend is on file for STXS.

2026 is still running; the price is −39.57% year to date. The strongest complete calendar year on file is 2019 at +389.81%; the weakest is 2022 at −66.61%. Of the 9 complete calendar years on file, 6 finished higher.

Peer Comparison

Stereotaxis, Inc. (STXS) operates in the Medical Instruments & Supplies industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Stereotaxis, Inc. STXS $139.28M —
Intuitive Surgical, Inc. ISRG $131.38B 42.4
Becton, Dickinson and Company BDX $50.32B 32.0
Medline Inc. MDLN $49.23B 45.7

The Medical Instruments & Supplies industry average P/E ratio is 35.6x. Stereotaxis, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Instruments & Supplies Stocks

ISRG

Intuitive Surgical, Inc.

$131.38B

 BDX

Becton, Dickinson and Company

$50.32B

 MDLN

Medline Inc.

$49.23B

 ALC

Alcon Inc.

$34.08B

 RMD

ResMed Inc.

$32.94B

 WST

West Pharmaceutical Services, Inc.

$23.93B
View all Medical Instruments & Supplies stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Stereotaxis, Inc.

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as Genesis RMN, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN System, which is designed to enhance the accessibility of Robotic Magnetic Navigation by reducing the lengthy construction cycle necessary to install prior generation RMN systems. It also offers Odyssey, a Synchrony and SynX Solution offer integrated, real-time information solution to manage, control, record and share procedures across networks; and x-ray systems. In addition, the company offers disposables and other accessories, including MAGiC catheter, a robotically navigated magnetic ablation catheter designed to perform minimally invasive cardiac ablation procedures; MAGiC Sweep, a mapping catheter; QuikCAS, an automated catheter advancement single-use disposable device; iCONNECT; and V-CAS devices. Further, it provides interventional devices under the Map-iT, MAGiC, and EMAGIN brands, and other related devices. It markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri.

Visit website →